ArticleScience immunology2024
AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans.
Abstract read
In one paragraph
Article in Science immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Next-generation vaccine adjuvants: Integrating nanotechnology, systems immunology, and computational approaches for precision vaccinology.Human vaccines & immunotherapeutics · 2026Review
- Targeting T follicular helper cells for lifelong health.Nature reviews. Drug discovery · 2026Review
- Review
- Mechanisms Underlying the Induction of Immunological Imprinting by RNA Viruses and Intervention Strategies.Viruses · 2026Review
- Vaccine Adjuvants and Delivery Systems: A Comprehensive Review.International journal of molecular sciences · 2026Review
- Recent Advances, Bottlenecks, and Future Directions inVaccines · 2026Review
- Low effectiveness of influenza vaccines vis-à-vis mechanism of protection by vaccines - potential causes and recommendations to improve control of influenza.Frontiers in immunology · 2026Review
- Development of an 8-valentFrontiers in immunology · 2026Article
- Review
- Influenza vaccine based on AS03-adjuvanted chimeric HA induces long-lived stalk-specific plasma cells in bone marrow and lymph nodes of nonhuman primates.Nature immunology · 2025Article
- Adjuvant-dependent protection of SARS-CoV-2 spike vaccines: comparative immunogenicity of human-applicable formulations.Journal of virology · 2025Article
- Future Goals and Long-term Vision of the Infectious Diseases Clinical Research Consortium/Vaccine and Treatment Evaluation Unit Network.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Review
- Moloney Murine Leukemia Virus-like Nanoparticles Pseudo-Typed with SARS-CoV-2 RBD for Vaccination Against COVID-19.International journal of molecular sciences · 2025Article
- Modular assembly and immunological evaluation of a promising bioconjugate nanovaccine against Klebsiella pneumoniae O2 serotype.NPJ vaccines · 2025Article
- Altered baseline immunological state and impaired immune response to SARS-CoV-2 mRNA vaccination in lung transplant recipients.Cell reports. Medicine · 2025Article
- Linking vaccine adjuvant mechanisms of action to function.Science immunology · 2025Review
- Nucleic acid vaccines: innovations, efficacy, and applications in at-risk populations.Frontiers in immunology · 2025Review
- Adjuvant combination and antigen multimerization shape neutralizing antibody and T cell responses to a SARS-CoV-2 RBD subunit vaccine.Frontiers in immunology · 2025Article
- An Evaluation of the Cellular and Humoral Response of a Multi-Epitope Vaccine Candidate Against COVID-19 with Different Alum Adjuvants.Pathogens (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Lilit GrigoryanInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-9255-1453
Yupeng FengInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0001-8550-2787
Lorenza BellusciFood and Drug Administration, Silver Spring, MD 20993, USA.ORCID 0000-0001-9945-1706
Lilin LaiDepartment of Pediatrics and Department of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory School of Medicine, Atlanta, GA 30329, USA.
Bushra WaliDepartment of Pediatrics and Department of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory School of Medicine, Atlanta, GA 30329, USA.
Madison EllisDepartment of Pediatrics and Department of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory School of Medicine, Atlanta, GA 30329, USA.ORCID 0000-0002-0325-5477
Meng YuanDepartment of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-9754-4503
Prabhu S ArunachalamInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0003-0090-5689
Mengyun HuInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0003-4495-7501
Sangeeta KowliInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0003-0362-572X
Sheena GuptaInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-6126-1170
Sofia Maysel-AuslenderInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.
Holden T MaeckerInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0003-0795-9946
Hady SamahaDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0002-9124-7820
Nadine RouphaelDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0002-2512-7919
Ian A WilsonDepartment of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-6469-2419
Alberto C MorenoDepartment of Medicine, Emory Vaccine Center, Emory National Primate Research Center, Emory University School of Medicine, Atlanta, GA 30329, USA.ORCID 0000-0002-3031-7194
Mehul S SutharDepartment of Pediatrics and Department of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory School of Medicine, Atlanta, GA 30329, USA.ORCID 0000-0002-2686-8380
Surender KhuranaFood and Drug Administration, Silver Spring, MD 20993, USA.ORCID 0000-0002-0593-7965
Stéphane PilletMedicago Inc., Québec, QC G1V 3V9, Canada.ORCID 0000-0002-7604-7855
Nathalie CharlandMedicago Inc., Québec, QC G1V 3V9, Canada.
Brian J WardMedicago Inc., Québec, QC G1V 3V9, Canada.ORCID 0000-0003-3251-958X
Bali PulendranInstitute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0001-6517-4333
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MVACCINE INDUCED IMMUNITY IN THE YOUNG AND AGEDU19AI057266 · NIAID · EMORY UNIVERSITY · PI Rafi Ahmed · 2003 to 2026
$81.7MNIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00017 · NIAID · EMORY UNIVERSITY · PI LOWEN, ANICE · 2021 to 2025
$27.3MStructure-based design of broadly protective coronavirus vaccinesP01AI167966 · NIAID · UNIVERSITY OF WASHINGTON · PI BALI PULENDRAN · 2022 to 2026
$15.3MSystems biological assessment of T cell responses to vaccinationU19AI167903 · NIAID · STANFORD UNIVERSITY · PI BALI PULENDRAN · 2022 to 2026
$13.2MBill & Melinda Gates Foundation INV-004923NIAID NIH HHS 75N93021C00017NIAID NIH HHS P01 AI167966NIAID NIH HHS U19 AI057266NIAID NIH HHS U19 AI167903NIH HHS P51 OD011132
Abstract
Vaccine adjuvants increase the breadth of serum antibody responses, but whether this is due to the generation of antigen-specific B cell clones with distinct specificities or the maturation of memory B cell clones that produce broadly cross-reactive antibodies is unknown. Here, we longitudinally analyzed immune responses in healthy adults after two-dose vaccination with either a virus-like particle COVID-19 vaccine (CoVLP), CoVLP adjuvanted with AS03 (CoVLP+AS03), or a messenger RNA vaccination (mRNA-1273). CoVLP+AS03 enhanced the magnitude and durability of circulating antibodies and antigen-specific CD4
Indexed as
alpha-TocopherolCOVID-19Influenza, HumanInfluenza VaccinesPolysorbatesSqualeneAdultAntibodies, ViralCOVID-19 VaccinesDrug CombinationsHumansMemory B Cellsalpha-TocopherolAntibodies, ViralAS03 adjuvantCOVID-19 VaccinesDrug CombinationsInfluenza VaccinesPolysorbatesSqualene
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.